The promise of minocycline in neurology

Carney, 1974, Minocycline excretion and distribution in relation to renal function in man, Clin Exp Pharmacol Physiol, 1, 299, 10.1111/j.1440-1681.1974.tb00552.x

MacDonald, 1973, Pharmacokinetic studies on minocycline in man, Clin Pharmacol Ther, 14, 852, 10.1002/cpt1973145852

Elkayam, 1999, Minocycline-induced autoimmune syndromes: an overview, Semin Arthritis Rheum, 28, 392, 10.1016/S0049-0172(99)80004-3

Seukeran, 1997, Benefit-risk assessment of acne therapies, Lancet, 349, 1251, 10.1016/S0140-6736(05)62445-2

Yrjanheikki, 1998, Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia, Proc Natl Acad Sci USA, 95, 15769, 10.1073/pnas.95.26.15769

Yrjanheikki, 1999, A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window, Proc Natl Acad Sci USA, 96, 13496, 10.1073/pnas.96.23.13496

Wang, 2002, Delayed minocycline but not delayed mild hypothermia protects against embolic stroke, BMC Neurol, 2, 2, 10.1186/1471-2377-2-2

Arvin, 2002, Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury, Ann Neurol, 52, 54, 10.1002/ana.10242

Tsuji, 2004, Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model, Exp Neurol, 189, 58, 10.1016/j.expneurol.2004.01.011

Fagan, 2004, Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection, Exp Neurol, 186, 248, 10.1016/j.expneurol.2003.12.006

Xu, 2004, Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats, BMC Neurol, 4, 7, 10.1186/1471-2377-4-7

Power, 2003, Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases, Ann Neurol, 53, 731, 10.1002/ana.10553

Yong, 2001, Metalloproteinases in biology and pathology of the nervous system, Nat Rev Neurosci, 2, 502, 10.1038/35081571

Stuve, 1996, Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9, Ann Neurol, 40, 853, 10.1002/ana.410400607

Golub, 1984, Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease, J Periodontal Res, 19, 651, 10.1111/j.1600-0765.1984.tb01334.x

Paemen, 1996, The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors, Biochem Pharmacol, 52, 105, 10.1016/0006-2952(96)00168-2

Ryan, 2001, Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity, Curr Med Chem, 8, 305, 10.2174/0929867013373598

Brundula, 2002, Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis, Brain, 125, 1297, 10.1093/brain/awf133

Popovic, 2002, Inhibition of autoimmune encephalomyelitis by a tetracycline, Ann Neurol, 51, 215, 10.1002/ana.10092

Nessler, 2002, Effect of minocycline in experimental autoimmune ncephalomyelitis, Ann Neurol, 52, 689, 10.1002/ana.10353

Wells, 2003, Neuroprotection by minocycline facilitates significant recovery from spinal cord injury, Brain, 126, 1628, 10.1093/brain/awg178

Lee, 2003, Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat, J Neurotrauma, 20, 1017, 10.1089/089771503770195867

Stirling, 2004, Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury, J Neurosci, 24, 2182, 10.1523/JNEUROSCI.5275-03.2004

Teng, 2004, Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury, Proc Natl Acad Sci USA, 101, 3071, 10.1073/pnas.0306239101

Sanchez Mejia, 2001, Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction, Neurosurgery, 48, 1393, 10.1227/00006123-200106000-00051

Du, 2001, Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease, Proc Natl Acad Sci USA, 98, 14669, 10.1073/pnas.251341998

Wu, 2002, Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease, J Neurosci, 22, 1763, 10.1523/JNEUROSCI.22-05-01763.2002

He, 2001, Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum, Brain Res, 909, 187, 10.1016/S0006-8993(01)02681-6

Tomas-Camardiel, 2004, Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system, Neurobiol Dis, 16, 190, 10.1016/j.nbd.2004.01.010

Chen, 2000, Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease, Nat Med, 6, 797, 10.1038/80538

Wang, 2003, Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease, Proc Natl Acad Sci USA, 100, 10483, 10.1073/pnas.1832501100

Smith, 2003, Minocycline and doxycycline are not beneficial in a model of Huntington's disease, Ann Neurol, 54, 186, 10.1002/ana.10614

Hersch, 2003, Minocycline is protective in a mouse model of Huntington's disease, Ann Neurol, 54, 841, 10.1002/ana.21891

Hockly, 2003, Minocycline is protective in a mouse model of Huntington's disease: author reply, Ann Neurol, 54, 842, 10.1002/ana.21893

Zhu, 2002, Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice, Nature, 417, 74, 10.1038/417074a

Kriz, 2002, Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis, Neurobiol Dis, 10, 268, 10.1006/nbdi.2002.0487

Van den Bosch, 2002, Minocycline delays disease onset and mortality in a transgenic model of ALS, Neuroreport, 13, 1067, 10.1097/00001756-200206120-00018

Tikka, 2002, Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease, Brain, 125, 722, 10.1093/brain/awf068

Yang, 2003, Minocycline enhances MPTP toxicity to dopaminergic neurons, J Neurosci Res, 74, 278, 10.1002/jnr.10709

Diguet, 2004, Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease, Eur J Neurosci, 19, 3266, 10.1111/j.0953-816X.2004.03372.x

Tikka, 2001, Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia, J Neurosci, 21, 2580, 10.1523/JNEUROSCI.21-08-02580.2001

Kim, 2004, Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells, Arch Pharm Res, 27, 314, 10.1007/BF02980066

Tikka, 2001, Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia, J Immunol, 166, 7527, 10.4049/jimmunol.166.12.7527

Zhang, 2003, Suppression of activated microglia promotes survival and function of transplanted oligodendroglial progenitors, Glia, 41, 191, 10.1002/glia.10172

Ekdahl, 2003, Inflammation is detrimental for neurogenesis in adult brain, Proc Natl Acad Sci USA, 100, 13632, 10.1073/pnas.2234031100

Wang, 2004, Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria, J Biol Chem, 279, 19948, 10.1074/jbc.M313629200

Scarabelli, 2004, Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO, J Am Coll Cardiol, 43, 865, 10.1016/j.jacc.2003.09.050

Gabler, 1992, Comparison of doxycycline and a chemically modified tetracycline inhibition of leukocyte functions, Res Commun Chem Pathol Pharmacol, 78, 151

Amin, 1996, A novel mechanism of action of tetracyclines: effects on nitric oxide synthases, Proc Natl Acad Sci USA, 93, 14014, 10.1073/pnas.93.24.14014

Kloppenburg, 1995, The influence of tetracyclines on T cell activation, Clin Exp Immunol, 102, 635, 10.1111/j.1365-2249.1995.tb03864.x

Kloppenburg, 1996, The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes, Antimicrob Agents Chemother, 40, 934, 10.1128/AAC.40.4.934

Lin, 2001, Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons, Neurosci Lett, 315, 61, 10.1016/S0304-3940(01)02324-2

Andes, 2002, Animal model pharmacokinetics and pharmacodynamics: a critical review, Int J Antimicrob Agents, 19, 261, 10.1016/S0924-8579(02)00022-5

Colovic, 2003, Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat, J Chromatogr B Analyt Technol Biomed Life Sci, 791, 337, 10.1016/S1570-0232(03)00247-2

Saivin, 1988, Clinical pharmacokinetics of doxycycline and minocycline, Clin Pharmacokinet, 15, 355, 10.2165/00003088-198815060-00001

Zhang, 2003, Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS, Ann Neurol, 53, 267, 10.1002/ana.10476

Kriz, 2003, Efficient three-drug cocktail for disease induced by mutant superoxide dismutase, Ann Neurol, 53, 429, 10.1002/ana.10500

Giuliani, 2004, Synergistic activity of minocycline and glatiramer acetate in an animal model of multiple sclerosis, Mult Scler, 9, S76

Nelissen, 2003, Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy, Brain, 126, 1371, 10.1093/brain/awg129

Bonelli, 2003, Minocycline for Huntington's disease: an open label study, Neurology, 60, 883, 10.1212/01.WNL.0000049936.85487.7A

Thomas, 2004, Minocycline in Huntington's disease: a pilot study, Mov Disord, 19, 692, 10.1002/mds.20018

2004, Minocycline safety and tolerability in Huntington disease, Neurology, 63, 547, 10.1212/01.WNL.0000133403.30559.FF

Gordon, 2004, Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis, Neurology, 62, 1845, 10.1212/01.WNL.0000125321.92112.7E

Metz, 2004, Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis, Ann Neurol, 55, 756, 10.1002/ana.20111